XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue:        
Total revenue $ 131,872 $ 115,860 $ 376,509 $ 327,132
Cost of revenue:        
Intangible asset amortization - cost of revenue 2,707 2,917 7,959 8,741
Total cost of revenue 40,590 36,850 115,950 107,741
Gross profit 91,282 79,010 260,559 219,391
Operating expenses:        
Research and development 15,981 17,574 49,965 50,004
Selling and marketing 24,455 22,612 74,225 70,610
General and administrative 27,278 25,742 93,417 83,697
Impairment of assets 0 185 20,505 614
Total operating expenses 68,336 66,993 239,977 207,424
Income from operations 22,946 12,017 20,582 11,967
Other income (loss), net (4,057) 4,831 6,985 10,334
Income before income taxes 18,889 16,848 27,567 22,301
Income tax (benefit) provision (248) 1,693 2,363 3,276
Net income $ 19,137 $ 15,155 $ 25,204 $ 19,025
Earnings per share:        
Basic (in USD per share) $ 0.24 $ 0.20 $ 0.32 $ 0.25
Diluted (in USD per share) $ 0.24 $ 0.19 $ 0.32 $ 0.25
Shares used to compute earnings per common share:        
Basic (in shares) 78,725,139 77,013,831 78,384,184 76,107,302
Diluted (in shares) 79,691,703 78,464,654 79,946,386 77,339,897
Testing revenue        
Revenue:        
Total revenue $ 127,756 $ 109,536 $ 357,328 $ 306,809
Cost of revenue:        
Cost of revenue 33,777 29,029 94,444 82,928
Product revenue        
Revenue:        
Total revenue 3,301 3,188 10,479 10,631
Cost of revenue:        
Cost of revenue 3,015 1,792 6,186 6,310
Biopharmaceutical and other revenue        
Revenue:        
Total revenue 815 3,136 8,702 9,692
Cost of revenue:        
Cost of revenue 1,091 3,112 7,361 9,762
Intangible Asset Amortization        
Operating expenses:        
Intangible asset amortization - operating expenses $ 622 $ 880 $ 1,865 $ 2,499